<DOC>
	<DOCNO>NCT02268838</DOCNO>
	<brief_summary>This single-center , placebo-controlled , randomize , ascend dose , double-blind study . This study evaluate ascend dos 50 , 100 , 200 , 400 mg E6007 . This study consist 5 step , 1 5 . In step 1 4 ( ascend dose 50 , 100 , 200 , 400 mg ) , subject randomly assign 6:2 ratio ( E6007 : placebo ) receive single dose study drug fast condition . Following 3 day washout period , subject receive study drug daily 7 day start fifth day single dose administration . For step 3 ( 200 mg ) , subject subsequently least 17 day washout period escalate step 5 ( 200 mg ) receive single dose E6007 fed condition , evaluate food effect study drug .</brief_summary>
	<brief_title>Single/ Multiple-Dose Study E6007 Healthy Japanese Male Subjects</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion Subjects must meet follow criterion include study : 1 . Healthy Japanese male subject age 20 44 year time inform consent . 2 . Has voluntarily consent , write , participate study . 3 . Has thoroughly brief condition participation study , willing able comply condition . Exclusion criterion Subjects meet follow criterion exclude study : 1 . Has clinically significant medical condition require treatment within 8 week initial study drug administration , history clinically significant infection require treatment within 4 week initial drug administration . 2 . History surgical treatment resection liver , kidney , Gastrointestinal tract , may affect Pharmacokinetic profile study drug . 3 . Ineligible study participation opinion investigator subinvestigator .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>E6007</keyword>
	<keyword>Healthy Japanese male subject</keyword>
</DOC>